# Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

## Materials

| Antibodies | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| For commercial reagents, provide supplier name, catalogue number and RRID, if available. | | √ |

| Cell materials | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| **Cell lines:** Provide species information, strain. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID | Section: Method; paragraph: Cell culture, lines 109 to 111.<br>The human renal cancer cell line 786-O (WHELAB C1043) and immortalized renal tubular epithelial cell HK-2 (WHELAB C116) were provided by SHANGHAI WHELAB BIOCIENCE LIMITED. | |
| **Primary cultures:** Provide species, strain, sex of origin, genetic modification status. | | √ |

| Experimental animals | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| **Laboratory animals:** Provide species, strain, sex, age, genetic modification status. Provide accession number in repository **OR** supplier name, catalog number, clone number, **OR** RRID | | √ |
| **Animal observed in or captured from the field:** Provide species, sex and age where possible | | √ |
| **Model organisms:** Provide Accession number in repository (where relevant) **OR** RRID | | √ |

| Plants and microbes | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| **Plants:** provide species and strain, unique accession number if available, and source (including location for collected wild specimens) | | √ |
| **Microbes:** provide species and strain, unique accession number if available, and source | | √ |

| Human research participants | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | Section: Method; paragraph: Clinical samples, lines 117 to 119.<br>The study protocol was approved by the First Affiliated Hospital of Guangxi Medical University Ethics Review Committee (Approval Number: 2023-E302-01) | |
| Provide statement confirming informed consent obtained from study participants. | Section: Method; paragraph: Clinical samples, lines 119 to 120.<br>Researchers had informed all subjects and obtained informed consent from them. | |
| Report on age and sex for all study participants. | | √ |

## Design

| Study protocol | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| For clinical trials, provide the trial registration number **OR** cite DOI in manuscript. | | √ |

| Laboratory protocol | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| Provide DOI or other citation details if detailed step-by-step protocols are available. | | √ |

| Experimental study design (statistics details) | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| State whether and how the following have been done**, or** if they were not carried out. | | √ |
| Sample size determination | | √ |
| Randomisation | | √ |
| Blinding | | √ |
| Inclusion/exclusion criteria | | √ |

| Sample definition and in-laboratory replication | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| State number of times the experiment was replicated in laboratory | | √ |
| Define whether data describe technical or biological replicates | | √ |

| Ethics | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | Section: Method; paragraph: Clinical samples, lines 117 to 119.<br>The study protocol was approved by the First Affiliated Hospital of Guangxi Medical University Ethics Review Committee (Approval Number: 2023-E302-01) | |
| Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval. | | √ |
| Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why. | | √ |

| Dual Use Research of Concern (DURC) | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval | | √ |

## Analysis

| Attrition | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance. | | √ |

| Statistics | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| Describe statistical tests used and justify choice of tests. | Section: Method; paragraph: Statistics, lines 145 to 150.<br><br>Statistical analyses were conducted using SPSS 22.0 and GraphPad Prism 8.0.2. Student's t-test, one-way ANOVA, and rank sum test were employed for comparing parametric and non-parametric data. Univariate and multivariate Cox regression analyses were performed to analyze SNHG3-related clinicopathological features. Pearson's correlation coefficient was used to assess the linear relationship, and survival analysis was conducted using the log-rank test. Statistical significance was determined at $P < 0.05$. | |

| Data Availability | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| State whether newly created datasets are available, including protocols for access or restriction on access. | | √ |
| If data are publicly available, provide accession number in repository or DOI or URL. | Section: Method; paragraph: Bioinformatics analysis, lines 79 to 86.<br>To validate the findings, the original gene expression profile (GSE53757) was obtained from the Gene Expression Omnibus (GEO) database.<br>A dataset consisting of gene expression profiles from 72 normal tissues and 541 tumor tissues of ccRCC was downloaded from The Cancer Genome Atlas (TCGA) database | |
| If publicly available data are reused, provide accession number in repository or DOI or URL, where possible. | | √ |

| Code Availability | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| For all newly generated code and software essential for replicating the main findings of the study: | | √ |
| State whether the code or software is available. | | √ |
| If code is publicly available, provide accession number in repository, or DOI or URL. | | √ |

## Reporting

| Adherence to community standards | Yes (indicate where provided: section/paragraph) | n/a |
|---|---|---|
| MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR. | The authors have completed the MDAR reporting checklist.<br>Section: Footnote; paragraph: Reporting Checklist, line 429.<br>Reporting Checklist: The authors have completed the MDAR reporting checklist. | |
| State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript. | ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.<br>Section: Footnote; paragraph: Conflicts of Interest, lines 430 to 431.<br>Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form. The authors have no conflicts of interest to declare. | |

Article information: https://dx.doi.org/10.21037/tcr-24-1509